Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Multiple Myeloma

Explore clinical trials studying Relapsed/Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

49 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Multiple Myeloma trial results

Completed

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT01794507

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 117876 Tucson, Arizona, United States
  • Mayo Clinic /ID# 121495 Jacksonville, Florida, United States
  • Northwestern University Feinberg School of Medicine /ID# 117477 Chicago, Illinois, United States
  • University of Michigan Hospitals /ID# 80353 Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number : 0360002 Wollongong, New South Wales, Australia
  • Investigational Site Number : 0360001 Melbourne, Victoria, Australia
  • Hospital Mae de Deus Site Number : 0760002 Porto Alegre, Rio Grande do Sul, Brazil
  • Clinica São Germano- Site Number : 0760003 São Paulo, Brazil
View all 23 locations
View Trial Details
Active, Not Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Arkansas for Medical Sciences /ID# 243096 Little Rock, Arkansas, United States
  • Sylvester Comprehensive Cancer Center /ID# 243673 Miami, Florida, United States
  • Moffitt Cancer Center /ID# 243437 Tampa, Florida, United States
  • University of Maryland, Baltimore /ID# 243679 Baltimore, Maryland, United States
View all 49 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Stanford University School of Med /ID# 242809 Stanford, California, United States
  • Sylvester Comprehensive Cancer Center /ID# 243417 Miami, Florida, United States
  • Tulane University School of Medicine /ID# 244854 New Orleans, Louisiana, United States
  • American Oncology Partners of Maryland /ID# 244858 Bethesda, Maryland, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

NCT05286229

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • National Cancer Center Hospital East /ID# 240943 Kashiwa-shi, Chiba, Japan
  • Hokkaido University Hospital /ID# 242672 Sapporo, Hokkaido, Japan
  • Kanazawa University Hospital /ID# 240948 Kanazawa, Ishikawa-ken, Japan
  • Duplicate_Okayama Medical Center /ID# 240949 Okayama, Okayama-ken, Japan
View Trial Details

Related conditions